# Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT02951312** · PHASE2 · COMPLETED · sponsor: **Sunovion Respiratory Development Inc.** · enrollment: 12 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Glycopyrrolate Inhalation Solution 25mg
- **DRUG:** Glycopyrrolate Inhalation Solution 75mg
- **DRUG:** Glycopyrrolate Inhalation Solution 200mg
- **DRUG:** Glycopyrrolate Inhalation Solution 200mg Jet
- **DRUG:** Glycopyrrolate Inhalation Solution 500mg
- **DRUG:** Glycopyrrolate Inhalation Solution1000mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02951312
- **Lead sponsor:** Sunovion Respiratory Development Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02951312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02951312, "Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02951312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*